moxetumomab pasudotox-tdfk (Lumoxiti)
moxetumomab pasudotox-tdfk is an FDA-licensed reference biologic from AstraZeneca AB. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2018
Reference approved
Reference product
Lumoxiti moxetumomab pasudotox-tdfk
AstraZeneca AB
- Approved
- Sep 13, 2018
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for moxetumomab pasudotox-tdfk, in chronological order.
Reference approval
Approval date of the reference moxetumomab pasudotox-tdfk product.
7 yr 10 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
9 mo ago
Frequently asked questions
Are there biosimilars approved for moxetumomab pasudotox-tdfk (Lumoxiti)?
No 351(k) biosimilars or interchangeable biosimilars referencing moxetumomab pasudotox-tdfk are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.